Arina Fjodorova

The UK’s life sciences sector is at a pivotal moment... Despite Merck’s and AstraZeneca’s recent announcements, there are reasons for optimism. The convergence of AI and health innovation is creating new opportunities for growth - especially in the spaces where universities, hospitals and investors collaborate. Our CEO, Anne Lane, has written an op-ed in the Financial Times about her optimism for the sector. She highlights that, at UCLB, we’ve seen firsthand how research breakthroughs can become commercial success stories: £3bn external in investment since 2020, and 100+ spinout companies creating 2300+ jobs.  But the potential goes far beyond this. To truly unlock economic growth, the UK needs more early-stage funding to help academic research become market-ready, more scale-up venture capital and an easier-to-access NHS, to provide the market ‘pull’ for homegrown health innovations coming out of our universities. Read Anne's thoughts on what needs to change - and why the UK can still lead the next wave of medical breakthroughs (£): https://lnkd.in/eZGYiSc7

152

1 Comment

Our Direct Lending team has provided senior debt facilities to support Keensight Capital's acquisition of Bedfont Scientific Ltd, a leader in non-invasive breath diagnostics. This marks our first transaction with Keensight, reflecting our continued support for ambitious growth across the healthcare sector. Read more: https://lnkd.in/djmh3ree

146

1 Comment

At AMCE, innovation goes beyond technology - it’s about precision, people, and delivering an exceptional patient experience. In the latest feature by ARISE News, Dr. Boules Gabriel, MD, MBA, MRCP SCE, MSc Oncology, Clinical Director of Oncology, shares how AMCE is redefining cancer care in Africa by integrating state-of-the-art medical systems with world-class clinical expertise. He highlights AMCE’s investment in both advanced infrastructure and the skilled professionals who bring it to life - citing the radiotherapy department, where AI-powered linear accelerators with real-time imaging enable sub-millimetre tumor tracking, even as the patient breathes. This is not just about machines - it’s about building a sustainable, high-precision ecosystem of care. At AMCE, technology and talent converge to set a new benchmark for healthcare on the continent. #AMCE #HealthcareInnovation #MedicalExcellence #AfricaHealth #OncologyCare #HealthTech #FutureOfHealthcare #PatientCentredCare

116

3 Comments

'We need to move with the times' - Matthew Durdy, Chief Executive, Cell and Gene Therapy Catapult.   In this Pink Sheet interview, Matthew Durdy, CGT Catapult, discusses how recent changes in UK drug regulations could impact the #cell and #gene therapy industry, and how the Medicines and Healthcare products Regulatory Agency (MHRA)'s new reforms in decentralised manufacturing are a positive signal for the UK's #CellTherapy ecosystem.   Read the interview: https://lnkd.in/eK4AR8BG   #ATMPs #AdvancedTherapies Citeline

47

3 Comments

Clinical trials contribute £7.4 billion annually to the UK economy, supporting 65,000 jobs and generating £1.2 billion of revenue for the NHS. Throughout the past year, we've worked to further maximize this value through initiatives to accelerate clinical trial delivery and embed research culture across health and social care. We work with partners and key stakeholders in the UK Clinical Research Delivery programme to achieve the common aim of creating a faster, more efficient, more accessible and more innovative clinical research delivery system – making the UK a world leader in clinical trials. Read through just some of the ways NIHR is helping transform clinical trials in our Annual Report for 2024/25 👇

200

7 Comments

Our Gastroenterology colleagues have successfully introduced another biosimilar medicine (Ustekinumab) for the treatment of patients with Inflammatory Bowel Disease (IBD), as part of ongoing efforts to enhance care and improve value for the NHS. This is the third biosimilar product to be implemented at OUH for IBD, which includes long-term conditions such as Crohn’s disease and ulcerative colitis. The move is part of a nationally-supported approach to safely and effectively expand the use of biosimilar medicines across the NHS. Biosimilars are highly similar versions of already approved biological medicines. They are assessed and authorised according to the same rigorous standards of pharmaceutical quality, safety, and clinical effectiveness that apply to all biological treatments. The move to Ustekinumab, along with previous biosimilar switches, has saved the Trust an estimated £4.9 million – funds which can be reinvested into patient care and service improvements. The changeover to the biosimilar was carefully planned, with the pharmacy team, IBD specialist nurses, and consultant team all integral to the process, and colleagues ensured there was careful communication with and support for affected patients. Those patients who had additional questions or concerns were offered appointments in ad-hoc clinics, where they could discuss the change directly with a consultant and specialist pharmacist. 🗣️ Dr Oliver Brain, Consultant Gastroenterologist at OUH, said: “Good disease control is vital in managing inflammatory bowel disease, and we are pleased to have introduced this additional treatment option safely and smoothly. Biosimilars offer the same clinical benefits as the originator drug, while helping us make best use of NHS resources.” Thank you to all involved – you can read more in our news story ⬇️ 🔗 https://orlo.uk/kJ4cK

56

1 Comment

🧬 The pharma services sector is experiencing rapid growth, driven by factors such as chronic diseases, regulation and R&D. 🔗 Our 'Ones to Watch' report highlights the most successful companies contributing to life sciences and the UK economy: https://okt.to/o0dMgx #PharmaServices #LifeSciences #MandA

58

1 Comment

In our latest Making Market Access Real episode, our team explores the transformative impact of two landmark strategies—the NHS 10-Year Plan and the Life Sciences Sector Plan—on the uptake of medicines across the UK. It highlights how these plans aim to accelerate access to innovative treatments by streamlining regulatory approvals and embedding new medicines into clinical pathways more rapidly. https://lnkd.in/eszdcxDm

26

HEOR has joined EMIG - Ethical Medicines Industry Group! We are looking forward to participating in discussions on the NHS 10-Year Plan and the health system expert panel at the upcoming meeting. We recently shared our perspective on the NHS 10-Year Plan, exploring whether AI could be part of the solution to the challenges facing the health service. If you missed it, you can read it here in The BMJ: https://lnkd.in/edTwNc-8. #NHSplan #healthcareinnovation

31